Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project

M.C. Gillies, R.J. Walton, J. Liong, J.J. Arnold, Ian Mcallister, Nigel Morlet, A.P. Hunyor, R.H. Guymer, J.E. Keeffe, R.W. Essex, A. Herrera-Bond, B. Glastonbury, J.M. Simpson, D. Barthelmes

Research output: Contribution to journalArticle

  • 20 Citations

Abstract

Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice. Copyright © 2014 by Ophthalmic Communications Society, Inc.
LanguageEnglish
Pages188-195
JournalRetina: the Journal of Retinal and Vitreous Diseases
Volume34
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Macular Degeneration
Blindness
Software
Switzerland
New Zealand
Visual Acuity
Communication
Data Accuracy

Cite this

Gillies, M.C. ; Walton, R.J. ; Liong, J. ; Arnold, J.J. ; Mcallister, Ian ; Morlet, Nigel ; Hunyor, A.P. ; Guymer, R.H. ; Keeffe, J.E. ; Essex, R.W. ; Herrera-Bond, A. ; Glastonbury, B. ; Simpson, J.M. ; Barthelmes, D./ Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project. In: Retina: the Journal of Retinal and Vitreous Diseases. 2014 ; Vol. 34, No. 1. pp. 188-195
@article{961f67cec0714bc2ad2b578881e4d85d,
title = "Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project",
abstract = "Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2{\%}, predominantly classic 24.6{\%}, occult 52.0{\%}, idiopathic polypoidal choroidal vasculopathy 1.2{\%}, and retinal angiomatous proliferation 3.2{\%}. Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice. Copyright {\circledC} 2014 by Ophthalmic Communications Society, Inc.",
author = "M.C. Gillies and R.J. Walton and J. Liong and J.J. Arnold and Ian Mcallister and Nigel Morlet and A.P. Hunyor and R.H. Guymer and J.E. Keeffe and R.W. Essex and A. Herrera-Bond and B. Glastonbury and J.M. Simpson and D. Barthelmes",
year = "2014",
month = "1",
doi = "10.1097/IAE.0b013e318296b271",
language = "English",
volume = "34",
pages = "188--195",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

Gillies, MC, Walton, RJ, Liong, J, Arnold, JJ, Mcallister, I, Morlet, N, Hunyor, AP, Guymer, RH, Keeffe, JE, Essex, RW, Herrera-Bond, A, Glastonbury, B, Simpson, JM & Barthelmes, D 2014, 'Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project' Retina: the Journal of Retinal and Vitreous Diseases, vol 34, no. 1, pp. 188-195. DOI: 10.1097/IAE.0b013e318296b271

Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project. / Gillies, M.C.; Walton, R.J.; Liong, J.; Arnold, J.J.; Mcallister, Ian; Morlet, Nigel; Hunyor, A.P.; Guymer, R.H.; Keeffe, J.E.; Essex, R.W.; Herrera-Bond, A.; Glastonbury, B.; Simpson, J.M.; Barthelmes, D.

In: Retina: the Journal of Retinal and Vitreous Diseases, Vol. 34, No. 1, 01.2014, p. 188-195.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project

AU - Gillies,M.C.

AU - Walton,R.J.

AU - Liong,J.

AU - Arnold,J.J.

AU - Mcallister,Ian

AU - Morlet,Nigel

AU - Hunyor,A.P.

AU - Guymer,R.H.

AU - Keeffe,J.E.

AU - Essex,R.W.

AU - Herrera-Bond,A.

AU - Glastonbury,B.

AU - Simpson,J.M.

AU - Barthelmes,D.

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice. Copyright © 2014 by Ophthalmic Communications Society, Inc.

AB - Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice. Copyright © 2014 by Ophthalmic Communications Society, Inc.

U2 - 10.1097/IAE.0b013e318296b271

DO - 10.1097/IAE.0b013e318296b271

M3 - Article

VL - 34

SP - 188

EP - 195

JO - Retina

T2 - Retina

JF - Retina

SN - 0275-004X

IS - 1

ER -